Aryland heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

Details for Australian Patent Application No. 2008251557 (hide)

Owner AMR Technology, Inc. Bristol-Myers Squibb Company

Inventors Cui, Wenge; Guzzo, Peter R.; Molino, Bruce F.; Olson, Richard E.; Liu, Shuang

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2008251557

PCT Pub. Number WO2008/141081

Priority 60/917,189 10.05.07 US

Filing date 8 May 2008

Wipo publication date 20 November 2008

International Classifications

A61K 31/55 (2006.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

C07D 223/16 (2006.01) Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom

Event Publications

26 November 2009 PCT application entered the National Phase

  PCT publication WO2008/141081 Priority application(s): WO2008/141081

7 October 2010 Assignment before Grant

  AMR Technology, Inc.; Bristol-Myers Squibb Company The application has been assigned to Bristol-Myers Squibb Company; Albany Molecular Research, Inc.

27 September 2012 Amendment Made

  The nature of the amendment is: Amend the name of the inventor to read Molino, Bruce F.; Liu, Shuang; Cui, Wenge; Guzzo, Peter R.; Olson, Richard E. and Yet, Larry 2009

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008251558-Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

2008251556-Membrane module with multiple bottom headers and filtration process